(Q43567634)

24 November 2017

title

Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia (English)

1 reference

24 November 2017

Giles F

1

1 reference

24 November 2017

Cortes J

2

1 reference

24 November 2017

Garcia-Manero G

3

1 reference

24 November 2017

Kornblau S

4

1 reference

24 November 2017

Estey E

5

1 reference

24 November 2017

Kwari M

6

1 reference

24 November 2017

Murgo A

7

1 reference

24 November 2017

Kantarjian H

8

1 reference

24 November 2017

publication date

1 January 2001

1 reference

Investigational New Drugs

24 November 2017

published in

1 reference

24 November 2017

volume

19

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

13-20

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006432012394

24 November 2017

exact match

0 references

cites work

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

12 December 2020

FUNGAL METABOLITES. THE STRUCTURES OF THE NOVEL SESQUITERPENOIDS ILLUDIN-S AND -M

1 reference

12 December 2020

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

12 December 2020

Four decades of therapy for AML.

1 reference

12 December 2020

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

1 reference

12 December 2020

Clinical trials referral resource. Clinical trials of MGI-114

1 reference

12 December 2020

Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.

1 reference

12 December 2020

Topotecan in the treatment of hematologic malignancies.

1 reference

12 December 2020

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)

1 reference

12 December 2020

Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA h

1 reference

12 December 2020

Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents

1 reference

12 December 2020

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study

1 reference

12 December 2020

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

12 December 2020

Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy.

1 reference

12 December 2020

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

12 December 2020

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1 reference

12 December 2020

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

1 reference

12 December 2020

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

1 reference

12 December 2020

Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

1 reference

12 December 2020

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

1 reference

12 December 2020

Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).

1 reference

12 December 2020

Conclusions regarding leukemia long-term survival

1 reference

12 December 2020

Acute liver failure due to hepatic involvement by hematologic malignancy

1 reference

12 December 2020

Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes

1 reference

12 December 2020

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

12 December 2020

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.

1 reference

12 December 2020

Preclinical evaluation of illudins as anticancer agents.

1 reference

12 December 2020

Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.

1 reference

12 December 2020

Antibiotic substances from Basidiomycetes+. VII. Clitocybe illudens

1 reference

12 December 2020

The road to the cure of acute lymphoblastic leukemia: a personal perspective.

1 reference

12 December 2020

Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center

1 reference

12 December 2020

Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug

1 reference

12 December 2020

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

1 reference

12 December 2020

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

1 reference

12 December 2020

Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan

1 reference

12 December 2020

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

1 reference

12 December 2020

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

12 December 2020

1 reference

12 December 2020

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

1 reference

12 December 2020

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia

1 reference

12 December 2020

Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

12 December 2020

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents

1 reference

12 December 2020

Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft

1 reference

12 December 2020

The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia

1 reference

12 December 2020

Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006432012394

1 reference

Dimensions Publication ID

24 November 2017

1035271852

0 references

1 reference